Cart is empty A live-attenuated tuberculosis (TB) vaccine candidate in development at Texas Biomedical Research Institute (Texas Biomed) elicits a much more balanced and effective immune response compared to the existing vaccine used across much of the world, according to preclinical research published in Nature Communications.
Leave A Comment